Please assess the completion status of the following clinical trial:

Trial Title: A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Has a clinical diagnosis of DMD confirmed by validated genetic testing~* Is considered to be non-ambulatory, defined as unable to walk 10 meters without assistance or help at Screening.~* Male aged 10 to less than 18 years, at the time of Screening.~* Body weight of at least 25 kg at Screening.~* If receiving corticosteroid therapy, therapy was initiated at least six months prior to the baseline visit and a stable daily dose for at least 3 months prior to baseline~* Participant has a Performance of Upper Limb Module for DMD 2.0 (PUL 2.0) Entry Item A score ≥2.~* Able to perform spirometry and has sufficient Respiratory function defined as reproducible percent predicted FVC ≥50%.~* Has adequate cardiac function defined as left ventricular ejection fraction (LVEF) ≥45% by echocardiogram and if receiving cardiac medication, must be currently on a stable regimen and doses of cardiac therapy (at least 3 months prior to baseline Day 1)~* Participant and their parent/guardian/carer are willing and able to comply with scheduled visits, study medication administration and study procedures.~Key Exclusion Criteria:~* Participation in another clinical trial (non-interventional) or administration of any investigational product or experimental product within 12 weeks or 5 half-lives (whichever is longer) preceding Day 1.~* Exposure to more than 3 investigational products within the 12 months prior to Day 1.~* History of clinically significant bleeding or coagulation abnormalities or clinically significant abnormal coagulation parameters.~* Currently receiving antiplatelet or anticoagulant therapy or has taken medication with an antiplatelet or anticoagulant effect within 4 weeks prior Day 1~* Any evidence of clinically significant structural or functional heart abnormality (cardiomyopathy that is managed by ACEi or beta blockers is acceptable provided the LVEF inclusion criterion is met).~* Known history of or a positive test for hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibodies, human immunodeficiency virus (HIV) antibodies at Screening.~* Evidence of renal impairment and/or cystatin C \>1.4 mg/L.~* Received a live vaccine (including intranasal influenza vaccine) within 4 weeks prior to Day 1 or planned live vaccination during the study period.~* Asthma (if requiring regular medication), bronchitis/chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, pneumonia or the presence of any non-DMD respiratory illness that affects PEF and FVC or other respiratory measures.~* Requires day-time assisted mechanical or non-invasive ventilation (NIV) (night time NIV is permitted).~* Chronic use (daily intake \>14 days), within one month of Day 1, of beta-2 agonists or any use of other bronchodilating medication (e.g., inhaled steroids, sympathomimetics, anticholinergics).~* Used carnitine, creatine, glutamine, oxatomide, idebenone or other forms of coenzyme Q10 or vitamin E or any other nutritional or antioxidant supplements or herbal medicines or anabolic steroids other than standard corticosteroids or puberty testosterone supplementation within 4 weeks of Day 1.~* Has an increased risk for opportunistic infections or systemic medical conditions resulting in significantly compromised immune system function

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- ATL1102 25mg (Type: EXPERIMENTAL): ATL1102 25mg administered subcutaneously once weekly
- ATL1102 50mg (Type: EXPERIMENTAL): ATL1102 50mg administered subcutaneously once weekly
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is administered subcutaneously once weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).